This result supports the potential use of ICI inhibitors in CHL patients with high CTLA-4 expression and adverse IPS factors as personalized treatment based on immunological profiles, Additionally, it may lead to integration of immunological markers into prognostic scoring systems for CHL in the future. Here, CTLA4 is linked to classic Hodgkin lymphoma.